Pharmaniaga Bhd (7081) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pharmaniaga Bhd stock MYR 0.69, price MYR 0.76, that is 9.4% below the price, quality 29 out of 100. Rating: overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 0.5894 MYR – 2.77 MYR · fair‑value band 0.5185 MYR – 0.9605 MYR · the 0.7600 MYR price screens above the 0.6885 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Pharmaniaga Bhd in your weekly email
Every Wednesday you see whether Pharmaniaga Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharmaniaga Berhad, an investment holding company, operates as an integrated healthcare service provider in Malaysia, Indonesia, and internationally. The company operates through Logistics and Distribution, Manufacturing, and Indonesia segments.
Show moreShow less
It is involved in manufacturing, distribution, and marketing of pharmaceutical and medical products, such as generic drugs and over-the-counter medicines; supply and installation of medical and hospital equipment; and research and development of pharmaceutical products.
The company also produces and distributes food supplements. In addition, it distributes and trades diagnostic products; and develops OLIN digital platform, an integrated digital platform for ordering, inventory, billing, and sales operations.
Further, the company provides logistics services and primary care products for acute diseases and specialty care products for serious and chronic diseases. Pharmaniaga Berhad was founded in 1994 and is based in Shah Alam, Malaysia.
Stock analysis
Pharmaniaga Bhd (7081) currently trades at 0.7600 MYR, while our model-based Fair Value estimate is 0.6885 MYR, 9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 0.9200 MYR per share, and 5 of the 15 models we run sit above the 0.7600 MYR price.
Bear case: the Asset-Based group reads lowest at 0.1400 MYR, and 10 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.5185 MYR (bear) to 0.9605 MYR (bull), the price of 0.7600 MYR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pharmaniaga Bhd reported revenue of 3.9B MYR in FY2025 versus 4.8B MYR in FY2021, a compound −5.0%/yr. Reported net income was 48.5M MYR in FY2025, compounding −27.1%/yr from FY2021.
Key figures
Market cap 997M MYR (≈ $246M) Micro · P/E ratio 6.3 · P/S ratio 0.08 · EPS (TTM) 0.1200 MYR · Dividend yield 2.2% · Net margin 1.2% · Return on equity 33.7% · Return on assets (EBIT) 1.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −9%, 7081 screens richer than that median.
Fair Value models
Bear0.5185 MYRFair Value 0.6885 MYRBull0.9605 MYR
Price 0.7600 MYR · Downside -9.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0883 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings0.6700 MYR0.9200 MYR1.22 MYR77
Residual Income0.2700 MYR0.2900 MYR0.3300 MYR76
EPV0.5500 MYR0.6100 MYR0.6700 MYR74
All 15 models by family
DCF Models
Owner Earnings0.6700 MYR0.9200 MYR1.22 MYR77
Earnings-Based
Graham-Dodd0.2500 MYR0.7500 MYR1.00 MYR65
Lynch FV0.1600 MYR0.2300 MYR0.3000 MYR61
PEG = 1.00.1600 MYR0.2300 MYR0.3000 MYR57
EPV0.5500 MYR0.6100 MYR0.6700 MYR74
Multiples
P/E Multiple0.6100 MYR0.8100 MYR1.02 MYR63
P/S Multiple0.4700 MYR0.6300 MYR0.7900 MYR58
P/B Multiple0.7300 MYR0.9700 MYR1.21 MYR55
EV/EBIT0.7200 MYR1.14 MYR1.56 MYR64
EV/EBITDA0.8100 MYR1.26 MYR1.71 MYR66
EV/Revenue0.3600 MYR0.7400 MYR1.13 MYR51
Asset-Based
NCAV (Graham)0.1100 MYR0.1400 MYR0.2200 MYR53
Economic Profit
Residual Income0.2700 MYR0.2900 MYR0.3300 MYR76
ROIC Compounder0.5700 MYR0.6700 MYR0.7800 MYR72
Growth Earnings
Growth-Adj P/E0.5000 MYR0.7100 MYR0.9200 MYR67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.48/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.6%
Start year 2020 (pandemic). Over 10 years: +6.0% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−0.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.5%
Dividend (yield on the price)2.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.5% vs −9.4%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 3%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−9.4% · Below median
Profitability
Return on equity (12 months)33.7% · Top 25%
Return on assets2.2% · Below median
Net margin (12 months)1.4% · Below median
Operating margin (12 months)2.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)12.3% · Top 25%
Dividend yield (12 months)2.2% · Below median
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharmaniaga Bhd Fair Value". https://www.fairvalue-calculator.com/stock/7081
Frequently asked questions
Is Pharmaniaga Bhd (7081) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 0.6885 MYR versus a price of 0.7600 MYR, about 9% lower (overvalued).
What is the fair value of 7081?
Our model-based fair value for Pharmaniaga Bhd is 0.6885 MYR (as of Nov 8, 2026), built from audited fundamentals. The current price: 0.7600 MYR.
What is the quality score of 7081?
Pharmaniaga Bhd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmaniaga Bhd (7081)?
Our model-based price target is the fair value of 0.6885 MYR (as of Nov 8, 2026) from 15 valuation models. Cautious scenario 0.5185 MYR, optimistic scenario 0.9605 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmaniaga Bhd stock forecast for 2026?
Our models put fair value at 0.6885 MYR, about 9% lower versus a price of 0.7600 MYR (overvalued). Cautious scenario 0.5185 MYR, optimistic scenario 0.9605 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmaniaga Bhd (7081)?
Pharmaniaga Bhd reported trailing-twelve-month revenue of about 4.2B MYR (latest available figure, as of Nov 8, 2026).
Does Pharmaniaga Bhd pay a dividend?
Pharmaniaga Bhd currently shows a dividend yield of 2.24% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Pharmaniaga Bhd (7081) and when is the ex-dividend date?
Pharmaniaga Bhd pays a dividend of 0.017 MYR per share a year, a dividend yield of 2.2%. The last ex-dividend date was Sep 14, 2026. The payout ratio is 14.2% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Pharmaniaga Bhd (7081)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmaniaga Bhd it is 0.6885 MYR per share (as of Nov 8, 2026), against a price of 0.7600 MYR. It is the blended result of 15 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Pharmaniaga Bhd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 7081 trades above its calculated fair value: price 0.7600 MYR, fair value 0.6885 MYR, a gap of about −9% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7081?
No. The price is what the market pays today (0.7600 MYR); the fair value is what the company's own numbers justify (0.6885 MYR). For Pharmaniaga Bhd the two are 0.0715 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmaniaga Bhd worth?
The market values Pharmaniaga Bhd at about 997M MYR (market capitalisation, as of Nov 8, 2026). Per share that is 0.7600 MYR; our models calculate a fair value of 0.6885 MYR per share.
What do the bullish and bearish scenarios say about 7081?
Our models span a range for Pharmaniaga Bhd: cautious scenario 0.5185 MYR, base 0.6885 MYR, optimistic 0.9605 MYR per share (as of Nov 8, 2026, price 0.7600 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7081?
Pharmaniaga Bhd trades at a price-to-earnings ratio of 6.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.6885 MYR is built from several models across several years. Other multiples: P/B 0.6, P/S 0.1, EV/EBITDA 1.8.
How solid is the balance sheet of Pharmaniaga Bhd (7081)?
Balance-sheet figures for Pharmaniaga Bhd (as of Nov 8, 2026): return on equity 33.7%, debt of 0.29 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 7081 from its 52-week high?
Pharmaniaga Bhd trades at 0.7600 MYR, about 53% below its 52-week high of 1.61 MYR and at the low of 0.7600 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.6885 MYR is for.
Which stocks are comparable to Pharmaniaga Bhd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmaniaga Bhd stock attractive at the current price?
The data as of Nov 8, 2026: price 0.7600 MYR, calculated fair value 0.6885 MYR (−9%), Quality Score 29/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7081 calculated?
We run Pharmaniaga Bhd through 15 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.6885 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pharmaniaga Bhd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmaniaga Bhd (7081)?
The closing price on Nov 6, 2026 was 0.7600 MYR. Our model-based fair value is 0.6885 MYR, about 9% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmaniaga Bhd right now?
A fairly wide model range (0.5185 MYR to 0.9605 MYR) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Pharmaniaga Bhd
How large is the market capitalisation of Pharmaniaga Bhd (7081)?
The market capitalisation of Pharmaniaga Bhd is 997M MYR (≈ $246M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmaniaga Bhd (7081)?
The price-to-sales ratio of Pharmaniaga Bhd is 0.08 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmaniaga Bhd (7081)?
Earnings per share at Pharmaniaga Bhd are 0.1200 MYR (price ÷ EPS = P/E 6.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharmaniaga Bhd (7081)?
The dividend yield of Pharmaniaga Bhd is 2.2% (payout 14.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharmaniaga Bhd (7081)?
The net margin of Pharmaniaga Bhd is 1.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmaniaga Bhd (7081)?
The return on equity (ROE) of Pharmaniaga Bhd is 33.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmaniaga Bhd (7081)?
On an EBIT basis the return on assets of Pharmaniaga Bhd is 1.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmaniaga Bhd (7081)?
The operating margin of Pharmaniaga Bhd is 2.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmaniaga Bhd (7081)?
Revenue at Pharmaniaga Bhd is growing +12.3% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharmaniaga Bhd (7081)?
Earnings per share at Pharmaniaga Bhd are growing −29.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Pharmaniaga Bhd (7081) generate?
The free cash flow of Pharmaniaga Bhd is −47.5M MYR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Pharmaniaga Bhd (7081) carry?
The net debt of Pharmaniaga Bhd is 709M MYR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharmaniaga Bhd in the live analysis
One click puts Pharmaniaga Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026